Biotech

Pharmaxis Ltd (ASX:PXS) Boehringer Ingelheim is Initiating Phase IIa Study for the Development of a New Treatment for Diabetic Retinopathy - a Leading Cause of Vision-Loss

🕔9/8/2017 1:38:29 PM

Boehringer Ingelheim and pharmaceutical research company Pharmaxis (ASX:PXS) (OTCMKTS:PXSLY) announce that Boehringer Ingelheim is initiating the Phase IIa study ROBIN. This marks the beginning of the clinical development program for BI 1467335 in a second indication targeting a severe diabetes complication. An already ongoing Phase II clinical study program is investigating the compound in NASH.

Read Full Article▸

Boehringer Ingelheim Initiates Phase IIa Study of Compound Acquired from Pharmaxis Ltd (ASX:PXS) in Debilitating Liver Disease NASH

🕔9/8/2017 12:01:53 PM

Boehringer Ingelheim and pharmaceutical company Pharmaxis (ASX:PXS) (OTCMKTS:PXSLY) announce that Boehringer Ingelheim has initiated a European and North American Phase IIa trial in NASH with BI 1467335 (formerly known as PXS-4728A), acquired from Pharmaxis in May 2015.

Read Full Article▸

Oventus Medical Ltd (ASX:OVN) Audited Financial Statements and Appendix 4E

🕔8/31/2017 1:27:22 PM

Australian medical device company, Oventus Medical Ltd. (ASX:OVN) is pleased to release its Appendix 4E with its full year audited general purpose financial report for the period ending 30 June 2017.

Read Full Article▸

Chapmans Limited (ASX:CHP) to Make Strategic Medicinal Cannabis Sector Investment

🕔8/29/2017 12:35:47 PM

The Directors of Chapmans Limited (ASX:CHP) are pleased to announce that the Company has entered into a Binding Heads of Agreement with MJ Life Sciences Pty Ltd, to make a strategic investment of US$500,000 in MJLS.

Read Full Article▸

Regeneus Ltd (ASX:RGS) Receives R&D Tax Incentive of $2.6m

🕔8/29/2017 11:29:46 AM

Regeneus (ASX:RGS), a clinical-stage regenerative medicine company, today reported that it has received $2.6m from the Australian Government's Research and Development tax incentive program for activities conducted during the financial year 2017.

Read Full Article▸

Rhinomed Ltd (ASX:RNO) Preliminary Final Report

🕔8/28/2017 6:45:01 PM

The Directors of Rhinomed Limited ASX:RNO) provide the following Report in relation to the Group for the year ended 30 June 2017.

Read Full Article▸

FINANCE VIDEO: Regeneus Ltd (ASX:RGS) Interview with John Martin on Progenza and the Platform Technology

🕔8/25/2017 10:15:41 AM

Regeneus Ltd (ASX:RGS) CEO John Martin talks on the release of the financial results following the company's significant progress with Japanese partner Asahi Glass Ltd (AGC) (TYO:5201)

Read Full Article▸

Banking & Finance

Read More

Oil Gas & Energy

Read More

Life Sciences

Read More

Social Media

Latest Headlines